- Entity formation
- Entity management
- M&A transaction support
- Private capital & hedge fund core services
- Private capital
- Hedge fund
- Technology solutions
- Other funds services
- SPV corporate services
- Agency services
- Loan administration
- Cross capital market services
- Structures implementation and management
- Private client services
- Reporting services
Explore content
Show all >Featured articles and media

Insights | Corporate Client Services
Voluntary carbon credits bolster green bonds
25 May 2023
Read >
Featured articles and media
Show all media for Private Capital & Hedge Fund Services >Featured articles and media
Show all media for Capital Markets >Featured articles and media
Show all media for Private Clients >Featured events

Events | Virtual
Bankruptcy and Restructuring: Navigating Distress in the Evolving Markets
22 Jun 2023
Learn more >
Events | Virtual
Private Funds Industry Live, Expanding Private Funds in Global Markets
10 Jan 2023
Watch the recording >
Events | Virtual
Private Funds Industry Live, Demystifying Private Capital Funds
6 Dec 2022
Watch the recording >- Home
- Our services
- Corporate Client Services
- Entity formation
- Entity management
- M&A transaction support
- Private Capital & Hedge Fund Services
- Private capital & hedge fund core services
- Private capital
- Hedge fund
- Technology solutions
- Other funds services
- Capital Markets
- SPV corporate services
- Agency services
- Loan administration
- Cross capital market services
- Private Clients
- Structures implementation and management
- Private client services
- Reporting services
- Corporate Client Services
- Our locations
- About us
- News & Insights
- Login
Amsterdam: the new pharma hub in Europe
13 November 2018
As of March 2019, Amsterdam will be the proud home of the European Medicines Agency (EMA). It’s been confirmed that the EMA will relocate its headquarters from London to Amsterdam due to Brexit. With a large number of pharma, medical technology companies, research institutions and more, the greater Amsterdam area has become one of the most attractive and fastest growing pharma and life science centres in the world.
“We see a large number of pharmaceuticals and Clinical Research Organisations preparing for the regulatory changes they’ll have to deal with in the short term” – says Jan Willem van Drimmelen, Head of Corporate Client Services at Intertrust. “Over the past months we’ve seen a significant increase in new clients, getting in contact with our experts in the Netherlands”.
The EMA is expected to provide job opportunities for 1,500 people, including lawyers, patent specialists and consultants who are expected to move to Amsterdam to be close to the organisation. In addition, pharmaceutical companies are likely to set up a subsidiary in the Netherlands. For the Dutch pharmaceutical industry, the arrival of the EMA will be a big boost noted by companies and investors worldwide.
The benefits of the Netherlands
- Internationally leading the Life Sciences & Health Sector
- Ranked No. 3 in the world by Forbes’ “Best Countries for Business”
- Perfect springboard into the European Union
- World-class health and research institutes
- Excellent logistics infrastructure and modern network of roads and highways
If you are considering relocating your business to the Netherlands, or to another EU-country, please don’t hesitate to get in contact. We have a team of specialists who can help you navigate all relevant local regulations and enable the setup of a legal entity, financial administration, payroll and all corporate secretarial services. Furthermore, we can support you with your local staffing and office space requirements providing tailor made solutions.